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Over the past decade, the ex-translation functions of secreted Aminoacyl-
tRNA Synthetases (AARSs) have been more elucidated.  Several of the secreted 
AARSs have been shown to be correlated to the immune system.  Secreted 
Tryosyl-tRNA Synthetase (YRS) and Histidyl-tRNA Synthetase 
(HRS)/Asparaginyl-tRNA Synthetase (NRS) induce polymorphonuclear leukocyte 
(PMN) and immature dendritic cell migration, respectively.   
In relation to macrophage, Tryptophanyl-tRNA Synthetase (WRS) plays a 
role in activating macrophage upon bacterial infection while Lysyl-tRNA 
Synthetase (KRS) and Glycyl-tRNA Synthetase (GRS) were both shown to have an 
influence on macrophages in a tumor microenvironment.  KRS secretion from 
tumor cells causes a proinflammatory response and migration of macrophage.  
GRS secretion from macrophage responds to Fas ligand secreted from tumor cells 
and binds to Cadherin-6 (CDH6) suppressing tumor growth.   
Previous observations showed that GRS antibodies were detected in 
patients’ blood with inflammatory induced myositis and interstitial lung disease.  In 




responses.  These observations lead me to further understand the role of GRS on 
macrophage.   In this study, I focused on explicating GRS role on macrophage and 
development of its derived peptides .   
In chapter one of this study, it was shown that macrophage, under stressed 
conditions, secret GRS in autocrine manner stimulating their polarization to 
become anti-tumor. GRS binds to macrophage receptor CELSR2, part of the super 
cadherin and G protein-coupled receptor (GPCR) families, activating the RAS-
RAF-MEK signaling pathway.  Upon activation, TNF-α, IL-6, and CXCL10 
cytokines are secreted shifting macrophages from M0 state to M1 type, which is 
antitumor, and induces phagocytosis.  GRS treatment in an initiation mice model, 
the growth of tumor was prevented or retarded.  This data shows that GRS is an 
important secreted cytokine that is needed for immune surveillance. 
In chapter two of this study, the active domain of GRS that binds to cancer 
cells was discovered and developed into a druggable peptide. GRS has been 
previously reported to kill cancers that expressed cadherin-6 (CDH6) by 
suppressing ERK signaling and inducing apoptosis.  Through computational 




active region of GRS.  Upon these results, synthesized peptides were derived and 
tested in-vitro and in-vivo.  The active region of the peptide was reduced to a 
conformational stable 8 and cyclic 25 amino acid, which greatly reduced the tumor 
growth by intra-tumor (IT) and intravenous (IV) injection.  In-vivo imaging system 
(IVIS) showed the fluorescent labeled peptides targeting the tumor.  These results 
show a developed GRS-derived peptide role as a potential drug candidate.  
This study shows secreted GRS has an important role in 
immunosurveillance.  GRS is secreted by macrophages as an alarmin that notices 
the abnormal environment formed during tumorigenesis.  Secreted GRS polarizes 
macrophage to produce antitumor cytokines to eliminate the malignant tumor cells 
and protect the body.  In addition, an active and stable peptide derived from GRS 
was developed.  The in-vitro and in-vivo testing showed promising results that 
GRS-derived peptide as a therapeutic agent against cancer.   
 
 
Keywords : Glycyl-tRNA Synthetase, Macrophage, Cancer, Peptide, Therapeutic 
drug,  Cadherin-6, CELSR2  
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Anti-tumor Polarization of Macrophage  














Tumor-associated macrophages (TAM) are classified to classically 
activated (M1) and alternatively activated (M2) subtypes depending on their roles 
in tumor growth and processes. In tumor microenvironment, M1 type macrophages 
are tamed by cancer-released factors to become M2 type that stimulates tumor 
angiogenesis, growth, metastasis, and immunosuppression(Gordon and Martinez, 
2010). However, it is not well known how the fate of macrophages is determined in 
tumor microenvironment.  
Cadherin EGF LAG seven-pass G-type receptors (CELSR) is a unique 
type of receptor.  It belongs to both cadherin superfamily and the G protein-
coupled receptor (GPCR) family.  CELSRs are important for neuronal system 
development and male fertility (refxx). Mutations in CELSRs have been associated 
with human diseases such as breast cancer.(refxx)  The CELSR have large 
ectodomains that consist of cadherin repeats.  Since CDH6 has been shown to bind 
to GRS, CELSR2 may also have the possibility to be a receptor for GRS.    
DuringAminoacyl- tRNA Synthetase (AARSs) are enzymes that ligate the 
appropriate amino acids onto their respective tRNA. Secreted human Tyrosyl-




terminal of 364 amino acids and C-terminal of 164 amino acids.  This shortened N-
terminal peptide, called mini-YRS, functions as an angiogenetic factor while C-
terminal peptide, which includes endothelial-monocyte-activating polypeptide II 
(EMAPII), functions as an immune stimulant.  Also Tryptophanyl-tRNA 
Synthetase (WRS) has two different functions.  Full length WRS is secreted from 
monocytes activating macrophage and the truncated N-terminal peptide has 
angiostatic cytokine activity.   
These finding encouraged us to investigate whether the secreted GRS 
would have additional roles in macrophage, particularly in the control of M1 and 
M2 polarization. The functional significance of GRS for macrophage activation 
and tumor suppression was demonstrated in vitro and in vivo. This work thus not 
only characterized the functional receptor, but also its implication for M1 












Secreted GRS induces M1 macrophage markers and activity 
To understand the effect of GRS on macrophage activities, RAW264.7 
were treated with GRS and determined the profile of the induced cytokines using 
multiplex cytokine array. The cytokines known to induce M1 polarization 
(Mantovani et al., 2004b; Mosmann and Coffman, 1989), such as CXCL10, IL-6 
and TNF-α(Gajewski et al., 2013), were significantly increased (Figure 1A). The 
transcriptional level of TNF-α in RAW264.7 cells treated with GRS or LPS was 
higher compared to IL-10 (Figure 1B). ). Primary macrophages were used to 
validate the effect of GRS on the secreted and transcription level of TNF-α, which 
dramatically increased with the addition of GRS or LPS relative to IL-10 (Figures 
1C and D). The effect of GRS on the expression level of macrophage polarization 
markers such as MHCII, presenting antigen to adaptive immune cells (M1 
marker)(Ziegler-Heitbrock et al., 1993), and CD206 (M2 marker)(Movahedi et al., 
2010), by  western blot and FACS analyses. In both assays, it was observed that 
GRS increased surface levels of MHCII similar to LPS (Figures 1E and F). In 




1 (Arg I) that are also the known M1 and M2 markers, respectively(Sica and 
Mantovani, 2012) (Figure 1G).   
Secreted GRS induces TNF-α secretion 
To determine whether GRS would be a major factor for the induction of 
M1 cytokines in cancer microenvironment, GRS was pre-incubated with anti-GRS 
antibody, GRS-induced TNF-α secretion was significantly reduced (Figure 2A). 
Using a transwell (pore size: 0.4 m), RAW264.7 were seeded in the upper 
chamber and H460 cells in the lower chamber in the presence or absence of anti-
GRS antibody and found that TNF-α secretion was significantly reduced by anti-
GRS antibody (Figure 2B). Next, GRS was tested to see induced TNF-α in-vivo, so 
cadherin positive (SN12C upper-right and H460 middle-bottom)and negative cell 
lines (RENCA) were transplanted.  GRS was shown to be secreted in the blood 
before TNF-α.  All of these results suggest that GRS would enhance the production 
of the M1-type signature cytokines from macrophages and play a crucial role in 
M1 polarization of cancer-associated macrophages. 
GRS induced phagocytosis in macrophage 
Since phagocytic activity is also one of the hallmarks for M1 macrophages, 
GRS was tested to see if it would stimulate phagocytic activity of macrophages by 




the increased phagocytic activity of GRS or LPS treated RAW264.7 cells by 
microscopy and quantified. (Figure 3A and B) Phagocytosis increased in dose-
dependent manner and was confirmed with primary cells (Figure 3C). Next the 
effect of GRS on phagocytosis-stimulating activity in vivo was examined using 
intravital monitoring system as previously described(Choe et al., 2013). For this 
experiment, LysM-GFP mouse was used in which macrophages/neutrophils can be 
monitored by GFP(Faust et al., 2000). This intravital phagocytosis system was 
validated by injecting LPS as immune stimulant. Significant increase of phagocytic 
activity was increased by macrophages/neutrophil as shown by LPS treatment 
(Figure D, left figure), further confirming the role of GRS in M1 polarization of 
macrophages. The Z stack analysis further confirmed the exact co-localization of 
macrophages/neutrophil (green) with beads (red) upon treatment with GRS and 
GRS-EV (Figure D, right figure) 
The M1 polarization of GRS is dependent on RAS-RAF-MEK signaling  
It has been shown that cadherins regulate MAPK signaling (Park et al., 
2012; Pece and Gutkind, 2000) and that MAPK signals are known to be critical for 
TNF-α secretion in macrophages(Means et al., 2000), which is a critical factor for 
macrophage M1 polarization(Saccani et al., 2006). To identify the GRS signal 




determined by immunoblotting. (Figure 4A). The JAK-STAT pathway is critical 
for determining if macrophage polarizes to M1 or M2 marker. p-STAT-1 is 
expressed for M1 macrophage and p-STAT3 is expressed for M2 macrophage 
(Figure 4B).  To  see if the GRS activation of M1 macrophages followed a different 
pathway than LPS.. LPS has been show to activate TNF-α secretion throught NF-
kB pathway.  Immunoblotting was performed and it is shown that LPS activates the 
NF-kB while GRS showed no effect (Figure 4C).  When macrophage was treated 
with MEK pathway, p-STAT-1 showed no activation and LPS treatment slightly 
reduced the p-STAT1.  (Figure 4D). Next, macrophage was treated with MEK 
inhibitor then GRS or LPS to see if the TNF-α secretion was reduced and lose its 
ability to perform phagocytosis.  MEK inhibition reduced TNF-α secretion and 
phagocytosis with GRS treatment but little effect was shown.  (Figure 4E,F) This 
data confirms that macrophage polarization is dependent on the MEK pathway.  In 
addition, LPS has little effect with MEK inhibition showing the GRS and LPS 
activate macrophage by different means.   
CELSR2 is identified as receptor for secreted GRS in macrophage 
To see the macrophage binding of GRS, RAW264.7 cells were treated with 
Alexa-fluor 647 (red fluorescence)-labeled GRS and BSA and observed that only 




cadherin (CDH6) was reported as the functional receptor for the death-inducing 
activity of GRS to cancer cells. Since GRS showed a different activity in 
macrophages, it was suspected that the functional receptor for GRS in macrophages 
differed. Potential GRS-binding proteins were searched from PharmDB database 
that shows the interactions of human proteins (Lee et al., 2012). The database 
suggested 32 proteins, which only CELSR2 (cadherin EGF LAG seven-pass G type 
receptor 2) was a membrane protein.  CELSR2, part of the cadherin superfamily, 
was first identified in drosophila (Usui et al., 1999), and its role in planar cell 
polarity (PCP), which is important for cell shape, structure, migration and function.  
However, its function in macrophages was not unveiled yet. CELSR2 was 
expressed in RAW264.7 cells but not in H460 cells. Interestingly, GRS showed 
preferential binding to CELSR2 in RAW264.7 cells although CELSR2 was 
detected in both of RAW264.7 and H460 cells (Figure 5B). This result suggests the 
possible involvement of additional factor(s) that would endow the specific binding 
of GRS to CELSR2 in macrophages.  
To determine the significance of CELSR2 for cell binding and M1 
polarization activity of GRS by suppressing the transcript of CELSR2, CELSR2 
was suppressed in macrophages with two independent si-RNAs targeting CELSR2 




suppression of CELSR2 (Figure 5C,D). In addition, the GRS-dependent induction 
of TNF-α secretion and transcription was decreased by the suppression of CELSR2 
(Figure 5D and 5E). Next, it was checked whether CELSR2 would give any effect 
on GRS-induced phagocytosis and found that GRS-induced phagocytosis was also 
lowered by CELSR2 suppression (Figure 5F). All of these results suggest the 
functional significance of CELSR2 for cell binding and M1 polarization activity of 
GRS in macrophages.  
M1 polarization activity of GRS effect on tumor growth 
GRS activity was then investigated whether its activity in M1 polarization 
of macrophages would play any significant role in the control of tumorigenesis. In 
our previous tumor regression model, GRS specifically suppressed tumor growth 
of renal carcinoma SN12C cells containing CDH6 receptor, but not RENCA cells 
lacking functional CDH6 (Park et al., 2012).  Since the effect of immune system 
against tumor formation would be more prominent at the initial stage of 
tumorigenesis, here it was investigated whether M1 polarization activity of GRS 
would give any tumor suppressive activity in a tumor initiation model. For this, 
GRS was treated once a day including the initial day of implantation of SN12C and 




observed that both of GRS suppressed the tumor growth regardless of CDH6 while 
giving little effect on body weight (Figure 6A,B,C,D). 
 Next, M1 and M2 macrophage infiltration was checked in the isolated 
tumor tissues and a significant increase of M1 (marked by MHCII staining) and 
decrease of M2 (marked by CD206 staining) was observed in macrophages in GRS 
or GRS-EV-treated tumors (Figure 6E). In addition, the tumor tissue treated with 
GRS showed an increase in apoptosis (Figure 6F).  
To give a brief summary of the GRS autocrine effect, a schematic was 













The role of GRS in the M1 polarization of macrophages against 
tumorigenesis and its secretion carried on extracellular vesicles from macrophages. 
Although classical M1 type macrophages would work to suppress tumorigenesis, 
they are tamed by the factors like CSF-1 and IL-10 released from cancer 
cells(Mantovani et al., 2004a) and polarized to M2 type which would promote 
tumor growth and mobilization(Sica et al., 2006). Although anti-tumorigenic M1 
and pro-tumorigenic M2 type macrophages show different profiles of secreting 
factors and cellular behavior(Mantovani and Sica, 2010), it is not well understood 
how the two fates are determined.  
This work demonstrated that secreted GRS an important factor for 
initiating cytokines that skew macrophages toward M1 type in a tumor 
microenvironment so that macrophages could work against tumor initiation. Based 
on the results here with our previous finding that GRS is rapidly released from 
cancer-associated macrophages to directly trigger cancer cell death (Park et al., 
2012), GRS appears to exert anti-tumorigenic activity in two distinct routes, 
namely, via direct apoptotic activity to cancer cells, and also through M1 
polarization activity of macrophages. These two activities may work together or 




However not much know about CELSR2 especially regarding the 
downstream signaling of these receptors.  The cadherin super-family is a group of 
calcium-dependent glycoproteins.  Since the first discovery of cadherins in the 
early 1980’s(Hyafil et al., 1981; Peyrieras et al., 1983), the cadherin family has 
greatly expanded into a superfamily, including classic cadherins (type I and II), 
protocadherins, desmogleins, desmocollins, and other cadherin-related 
proteins(Angst et al., 2001). While their functions in cell adhesion and migration, 
cytoskeletal organization, and morphogenesis have been well studied, their roles in 
cancer are also rapidly being uncovered(Christofori and Semb, 1999). While GRS 
was shown to work to cancer cells via CDH6, this work showed its M1 activation 
of macrophages via CELSR2 that is defined as non-classical seven-pass 
transmembrane family of cadherin. CELSR2 was also suggested to play a role in 
protein transport and secretion (Kjolby et al., 2010). The suggested functions of 
CELSR2 in cell migration and protein secretion appear to support the observed 
activities of GRS to macrophages although how GRS would activate CELSR2 
would require further studies. In this regard, GRS could be used as 







Figure 1. Secreted GRS induces macrophage M1 polarization.  (A) RAW264.7 
cells were treated with GRS (100 nM) for 6 hr. The cultured media were harvested 
to measure secreted cytokines. Cytokines profiles were determined by multiplex 
assay, unpaired t test, *P<.0005.  (B) RAW264.7 cells were treated with GRS (100 
nM) or LPS (50 ng/ml) for 4 hr and the transcript level of TNF-α and IL-10 was 




of a fold change after normalizing with β-actin mRNA, unpaired t test. (C) BMDM 
cells were subjected to GRS (100 nM) for 6 hours and the secretion of TNF-α and 
IL-10 was analyzed by ELISA, unpaired t test, *P<.0001. (D) Quantitative PCR 
(qPCR) analysis of TNF-α and IL-10 mRNA expression in BMDM cells after 
treatment with GRS (100 nM) for 4 hr, unpaired t test, *P<.0001.  Results are 
presented in-terms of a fold change after normalizing with β-actin. (E) After 24 hr 
incubation of RAW264.7 cells with GRS and LPS, the M1 and M2 polarization 
marker proteins, MHCII and CD206, respectively, were determined by 
immunoblotting (F) RAW264.7 cells were incubated with GRS or LPS for 24 hr 
and the induction of MHC II was determined by FACS analysis. (G) Quantitative 
PCR (qPCR) analysis of Arg I and iNOS mRNA expression in RAW cells after 






Figure 2. GRS controls TNF-α secretion in a tumor microenvironment. (A) 
GRS alone or GRS pre-incubated with anti-GRS antibody for 30 min and then 
added to macrophages for 6h. The secreted TNF-α was determined in culture media 
by ELISA, unpaired t test, *P<.005.  (B) Macrophages (RAW264.7) and cancer 
cells (H460) were co-cultured and then TNF-α secretion was monitored by ELISA. 




culture media, unpaired t test, *P<.01. (C) Cancer cells (5x106) were 
subcutaneously transplanted into nude mice, and blood was collected on the days 
indicated.  GRS and TNF-α secretion was determined by ELISA. n= 6 mice per 
group. 
 
Figure 3. GRS induces phagocytosis in macrophage (A)RAW264.7 cells treated 
with GRS and LPS for 12 hr were incubated with fluorescence-labeled 




by confocal microscopy. (B) After GRS treatment and LPS as a positive control to 
RAW264.7 cells, phagocytosis beads were added for 2 hr. To quantify the GRS 
induced-phagocytosis, the fluorescence intensity was determined by microplate 
reader. Unpaired t test, *P<.01. (C) BMDM cells were treated with GRS and LPS 
were treated in the same manner as above, unpaired t test, *P<.01. (D) To 
determine the effect of GRS and GRS-EVs on phagocytic activity of macrophages 
in vivo, they were intradermally injected into the ears of LysM-GFP mice. After 6 
hr incubation, Alexa594-conjugated particles (red fluorescence) were injected and 
the movement of macrophage/neutrophil (LysM, green) toward the particles were 
visualized with custom-built in vivo confocal microscopy for 90 min*.  Co-
localization of macrophages (green) treated with GRS. Scale bar represents 100 µm 










Figure 4. GRS activity is dependent on RAS-RAF-MEK pathway (A) RAW 
264.7 cells were treated with GRS (100nM) or LPS (50ng) for one hr and the 
phosphorylation of RAF, MEK and ERK was determined by Western blotting. (B) 
Cells were subjected to GRS or LPS (50ng) for one hr and the phosphorylation of 
JAK and STAT1 was shown by immunoblotting (C) Cells were subjected to GRS 
or LPS (50ng) for one hr and the phosphorylation of NF-κB was shown by western 
blotting.   (D)Cells were pre-treated with MAPK kinase inhibitor, 10 µM U0126 
(MEK inhibitor), for 1 hr and then 100 nM GRS  or 50ng LPS was added for 1 hr. 
Their effect on the phosphorylation of ERK and STAT1 was shown by Western 
blotting. (E) RAW246.7 cells were treated with MEK kinase inhibitor for 1hr and 
GRS or LPS was treated for 6 hr, the media was collected and the secretion of 
TNF-α was determined by ELISA, unpaired t test, *P<.0005. (F) MAPK kinase 
inhibitors 1.25 µM U0126 (MEK inhibitor) was treated to cells and GRS was 
treated to cells for 12 hr, phagocytosis beads were added for 2 hr. To quantify the 
GRS induced-phagocytosis, the fluorescence intensity was determined by 










Figure 5. CELSR2 is identified as a receptor for GRS and inhibition reduces 
GRS binding and M1 activities (A) RAW 264.7 cells were incubated with Alex-
Fluor 647 (red) labeled GRS or BSA (100 nM) for 30 min. Cell nuclei were stained 
by DAPI (blue) and the images were taken by confocal microscopy. (B) 
Biotinylated GRS (Biotin-GRS) was incubated with the protein extracts of 
RAW264.7 and H460 precipitated by streptavidin-sepharose. The GRS-bound 
proteins were subjected to SDS-PAGE and the presence of endogenous CELSR2 
was determined by immunoblotting with its specific antibody. (C) RAW 264.7 
cells were transfected with non-specific siRNA (si-con) or two siRNAs targeting 
the CELSR2 transcript (si-CELSR2 #1, #2). The knockdown of CELSR2 was 
determined by western blotting. (D) RAW264.7 cells were transfected with non-
specific siRNA (si-con) or siRNA targeting the CELSR2 transcript (si-CELSR2), 
and then incubated with biotin-GRS. (E) RAW 264.7 cells were transfected with 
two siRNAs targeting the CELSR2 transcript (si-CELSR2 #1, #2) and their effect 
on the phosphorylation of ERK was determined by Western blotting. (F) 
RAW264.7 cells transfected with anti-CELSR2 siRNAs as above were treated with 
GRS (100 nM) for 6 hr and the secretion of TNF-α was analyzed in culture media 
by ELISA, unpaired t test, *P<.005. (G) Macrophages were treated with si 
CELSR2 #1, #2 as mentioned above, then cells were incubated with GRS (100 nM) 




actin level, unpaired t test, *P<.01.  (H) Cells above were also treated with GRS for 
12 hr and further incubated with phagocytosis beads (green fluorescence). The 
phagocytic activity was determined by microplate reader, unpaired t test, *P<.0005, 
















Figure 6. GRS reduced tumor growth in-vivo initiation model. The activities of 
GRS or GRS-EVs against tumor initiation was validated by in vivo xenograft 
mouse model using renal carcinoma SN12C (CDH6 positive, left panel) and 
RENCA (CDH6 negative, right panel) cells. The cancer cells (1x107) were 




mg/kg) were delivered intraperitoneal injection to mice via once a day for 5 days 
included initial day of transplantation. n= 6 mice per group. (A) Tumor volumes 
were measured every 2 days after GRS treatment. (B) Relative size and weights of 
tumor initiation model (C) Body weights of initiation model were measured; n=3 
biological replicates, unpaired t test, *P<.0005. (D) Images of tumor of the tumor 
initiation model (E) To determine the type of infiltrated macrophages, the tumor 
tissues treated with GRS and GRS-EVs were stained with anti-MHCII and –CD206 
antibodies for immunohistochemistry. Scale bar indicates 100 µm.  (F) TUNEL 












MATERIALS AND METHODS 
Cell culture and materials   
RAW264.7 cells were grown in DMEM medium from Hyclone (Logan, UT, USA) 
containing 10% fetal bovine serum and 50 mg/ml streptomycin and penicillin 
(Hyclone). Bone marrow derived macrophages (BMDM) were harvested from 
C57B/6 mice. Bone marrow cells were isolated from femurs and tibias. After red 
blood cells were removed with ACK solution from Thermo Fisher Scientific  
(Waltham, MA, USA), bone marrow cells were incubated for 7 days with murine 
GM-CSF (20 ng/ml) from Peprotech (Rocky Hill, NJ, USA). The antibodies 
against GRS was purchsed from Neomics (Suwon, Korea), MHC II from Millipore 
(Billerica, MA, USA), CD206 from Abcam (Cambridge, UK), p-ERK, ERK, p-p38, 
p38 from Cell Signaling Technology (Danvers, MA, USA) and p-JNK, JNK from 
Santa Cruz Biotechnology (Dallas, TX, USA). Si-RNAs ‘5- 
AUAGGAACCACUCUGGUCAUCUUCC-3´ and ‘5 
AGCAGUAGCCCGUUACGCUCCUUGG-3’ targeting CELSR2 were obtained 
from Invitrogen (Carlsbad, CA, USA). MAPK kinase inhibitors (U0126, 







Preparation of recombinant human GRS   
Human GRS cDNA encoding 685 amino acids was subcloned into pET-28a 
(Millipore) with EcoRI and XhoI, and overexpressed in Escherichia coli Rosetta by 
0.5 mM IPTG. His-tagged GRS was then purified using nickel affinity 
chromatography (Invitrogen) following the manufacturer’s instruction. To remove 
lipopolysaccharide (LPS), the purified protein solution was dialyzed in pyrogen-
free potassium buffered saline (PBS, pH 7.4) containing 15% glycerol. After 
dialysis, the GRS-containing solution was filtered through Acrodisc unit with 
Mustang E membrane from Pall Corporation (Port Washington, NY, USA). 
Endotoxin was measured by limulus amebocyte lysate (LAL) assay from Pierce 
(Rockford, IL, USA). Recombinant GRS protein contained endotoxin less than 1 
EU/ml.  
Cell binding assay   
RAW264.7 cells were seeded into six-well dishes and incubated for 12 hr. Then, 
the biotinylated GRS was added to the culture medium and further incubated for 




25 mM Tris-HCl (pH 7.4) lysis buffer containing 150 mM NaCl, 2 mM EDTA, 1% 
Triton X-100, 1% sodium deoxycholate, 10 mM NaF, 1 mM sodium orthovanadate, 
10% glycerol and protease inhibitors and centrifuged at 18,000 g for 15 min. The 
extracted proteins were resolved by SDS/PAGE, and detected by streptavidin-
coupled HRP (Pierce). For biotinylation, recombinant GRS (1.5 mg) was incubated 
with 0.25 mg sulfo-NHS-SS-biotin (Pierce) in PBS for 2.5 hr at 4°C. Free biotins 
were quenched with glycine and removed by size exclusion column, PD10 from 
GE Healthcare (Chicago, IL, USA). To monitor cell binding of GRS by 
immunofluorescence staining, BSA and GRS were labeled with Alexa-Fluor 647 
(Life technologies). RAW cells were then seeded on 22 x 22 mm coverslips. 
Labeled BSA (100 nM) or GRS (100 nM) was added to the media for 30 min. Next 
the cells were washed with cold PBS two times. The cells were fixed with 4% 
formaldehyde from Affymetrix  (Santa Clara, CA, USA) for 10 minutes, washed 
two times, and then stained with DAPI (Life technologies) for 10 min and washed 
three times and mounted on the microscope slide. The cells were mounted and 
observed by confocal microscopy (Nikon A1, Tokyo, Japan).  
Immunofluorescence 
RAW264.7 cells were seeded on 22 x 22 mm cover glass. The conditioned cells 




The samples were blocked by CAS-blockTM (Thermo Scientific) for 30 min and 
then incubated with anti-GRS antibody for 2 hr. Anti-GRS antibody was captured 
with Alexa488-conjugated secondary antibody (Thermo Scientific). Nuclei were 
stained with DAPI (4',6-diamidino-2-phenylindole, Invitrogen). ER and Lyso 
tracker (Thermo Scientific) were used to stain intracellular endoplasmic reticulum 
and lysosomes, respectively. Before fixation, each tracker was incubated with the 
cells for 2 hr and visualized by confocal microscopy-A1R (Nikon). 
Flow cytometry analysis 
RAW264.7 cells were first incubated in staining buffer (PBS with 2% fetal calf 
serum and 0.1% NaN3) containing hamster and mouse IgGs from PharMingen (San 
Diego, CA, USA) for 15 min on ice to block non-specific binding. The cells were 
then stained with MHC class II antibody for 45 min on ice and analyzed by 
FACScan using CellQuest software (BD Biosciences). 
Phagocytosis assay   
Macrophage phagocytic activity was measured using the Vybrant Phagocytosis 
Assay Kit (Thermo Fisher Scientific). Briefly, RAW264.7 cells were seeded in a 
96-well plate. The cells were treated with GRS (100 nM) and LPS (50 ng/ml) for 
12 hr. After treatment, the cells were further incubated with fluorescein-labeled 




by trypan blue, and phagocytic activity was quantified by measuring fluorescence 
intensity using microplate reader (BMG Labtech FLUOstar OPTIMA, Ortenberg, 
Germany). For immunofluorescence phagocytosis assay, RAW264.7 cells were 
seeded on coverslips for 12 hr and serum starved for 2 hr. BSA (100 nM), GRS 
(100 nM) or LPS (50 ng/mL) was added to the media for 12 hr. The cells were 
fixed with 4% formaldehyde for 10 min, and then permeabilized with 0.1% Triton-
X in PBS for 5 min. The cells were then incubated with E.Coli (K12)-alexa fluor-
488 bioparticle (Thermo Fisher Scientific) for 10 min and washed two times, then 
stained with DAPI from Molecular Probes (Eugene, OR, USA) for 10 min and 
washed three times and mounted. The images were taken with confocal microscopy 
(Nikon A-1). 
ELISA and multiplex assay   
RAW264.7 cells were cultured in 12 well plates. Different amounts of GRS were 
added to the media. After 6 hr incubation, the media was collected and spun down 
by centrifugation at 3,000 g for 10 min. The secreted TNF-α and IL-10 were 
detected using the ELISA kit following manufacturer’s instruction (BD 
Biosciences, San Jose, CA, USA). The cytokine level of samples was measured by 
microplate reader (TECAN, Mannedorf, Swiss). For multiplex assay, TNF-α, IL-6, 




beads were purchased from R&D Science (Minneapolis, MN, USA). Standards and 
samples were incubated with the beads on plate shaker for 2hr. Second antibody 
was added to each well. After 1 hr incubation, streptavidn-PE solution was added 
and further incubated for 30 min. The beads were measured with luminex system 
(BioRad, Bioplex 200, Hercules, CA, USA) and analyzed by bioplex software 
(BioRad 6.0). 
qRT-PCR assay   
Cells were incubated on six-well dishes for 12 hr and then stimulated with His-
GRS (100 nM) for indicated times. Total RNAs were extracted by using RNeasy 
mini kit from QIAGEN (Germantown, MD, USA). cDNA was synthesized using 
maxima first strand cDNA synthesis kit (Thermo Fisher Scientific). qRT-PCR was 
performed with the primers specific to the TNF-α, IL-10, iNOS, Arg-I and β-actin.  
TNF-α: 5’-CTCAAAATTCGAGTGACAAGCCTG-3’(forward),  
5’-ATCGGCTGGCACCACTAGTT-3’(reverse),  
IL-10: 5’-AGACTTTCTTTCAAACAAAGGA-3’(forward),  
5’- ATCGATGACAGCGCCTCAG-3’(reverse),  





Arg-I: 5’- AAGAAAAGGCCGATTCACCT-3’ (forward),  
5’-CACCTCCTCTGCTGTCTTCC-3’ (reverse),  
β-actin: 5’-GGCTGTATTCCCCTCCATCG-3’ (forward),  
5’- CCAGTTGGTAACAATGCCAT -3’. To calculate the quantitative RNA level, 
samples were analyzed by Maxima SYBR Green/ROX qPCR master mix (Thermo 
Fisher Scientific) on Thermal Cycler DiceTM Real Time system (Takara, Shiga, 
Japan) according to manufacturer’s protocols. β-actin mRNA levels were used as 
internal controls.  
In vivo tumor model   
Xenograft experiments were performed in accordance with the University Animal 
Care and Use Committee guidelines at Seoul National University. For the initiation 
model, SN12C and RENCA cells (1 x 107) were injected subcutaneouly into the 
right flank of 8-week-old BALB/c female nude mice. Tumor volume was measured 
as length x width2 x 0.5 using caliper. The purified GRS and GRS-EVs were 
administrated by intraperitoneal injection in a single dosage of 6 mg/kg/day for 5 
days including the initial day of xenograft. Tumor weights and sizes were measured 





Intravital phagocytosis imaging   
The in vivo effect of GRS on phagocytic activity of macrophages was monitored by 
custom-built laser-scanning confocal microscopy. To implement 2D scanning, 
fastrotating polygonal mirror (Lincoln Laser, Phoenix, AZ, USA) and 
galvanometer (Cambridge Technology, Cambridge, MA, USA) were used. High-
sensitive photomultiplier tubes (Hamamatsu Photonics, Hamamatsu, Japan) were 
utilized to detect three-color fluorescence signals simultaneously. Three detection 
channels were split by dichroic mirrors and bandpass filters (Semrock, Rochester, 
NY, USA). Electric signals obtained from PMT were digitized by an 8-bit 3-
channel frame grabber (Matrox, Dorval, Canada). After acquired from the imaging 
system, 512x512 pixel images were then XY-shift compensated with Matlab 
(Mathworks, Natick, MA, USA) and reconstructed on either XZ/YZ axis by 
ImageJ software. For intravital phagocytosis imaging, the male LysM-GFP 
(Lysozyme M-GFP) mice (18-22 week old) were used. Mice were anaesthetized 
with mixture of Zoletil (30 mg/kg, Virbac, Carros, France) and xylazine (10 mg/kg, 
Bayer-Korea, Seoul, Korea). Alexa-405 (Thermo Fisher Scientific)-conjugated 
GRS (1 μg) was intradermally injected into mouse ear skin with 31G micro-
injector Hamilton syringe (Sigma-Aldrich). After 6 hr incubation, E.Coli (K12)-




injection sites and phagocytosis was visualized with confocal microscopy platform 
for 90 min. 
Immunohistochemistry   
The isolated tumors were stored in 4% formaldehyde from Junsei Chemical  
(Tokyo, Japan) for 24 hr. The tumor tissues were parafilmed blocked and sectioned 
to 10 µm by WooJung BSC  (Osong, South Korea).  The sections were incubated 
with anti-MHCII antibody (Millipore) or anti-CD206 (Abcam) and visualized with 
anti-mouse HRP conjugated antibody from Dako (Carpinteria, CA, USA) and DAB 
substrate (Dako). After visualization, the slides were counterstained with 
hematoxylin (Sigma-Aldrich). Immunohistochemical staining was analyzed by 
Optinity microscope (Lieca) with Toupview program. 
Data analysis 
Statistical Analysis Results from multiplex beads, phagocytosis, ELISA and qPCR 
data were presented as mean ± standard deviation. Statistical significance was 
computed with Microsoft Excel 2016 unpaired Student’s t test with a p value of < 
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Recently peptides have been the focus of drug development.  They are 
more selective to their target because of more interaction sites than small molecules 
making them highly selective and more efficacious.  Also peptides have less side 
effects, so they are well tolerated and safe.   Consequently, there is an increased 
interest in peptides in pharmaceutical research and development (R&D), and 
approximately 140 peptide therapeutics are currently being evaluated in clinical 
trials. The peptide drugs make up around 10% of the pharmaceutical market.  
An array of proteins are in an inactive forms in our bodies. They have to 
be cleaved to expose their active site.  Prepoinsulin is a zymogen, an inactive 
protein, needs to be cleaved to be active to be change to its active form called 
insulin.  It has been shown that Aminoacyl-tRNA Synthetases (ARSs) are cleaved 
are cleaved as well forming shorter peptides that have a different role than the full 
length.  For instance, Tyrosyl-tRNA Synthetase (YRS) is cleaved to generate two 
peptides with distinct activities.  N-terminal Tryptophanyl-tRNA Synthetase 
(WRS), designated mini-WRS is secreted to suppress angiogenesis.  
The cadherin superfamily is divided into five subfamilies: cadherins; 




Cadherins are important for cell to cell binding but there have been reports for their 
association to cancer growth and metastasis.  The loss of epithelial cadherin (E-
cadherin) is associated with poor prognosis and metastatic diseases, which is 
important to maintain epithelial cells’ structure. Cadherin 6 (CDH6), classical type 
II cadherin with extracellular repeats has been shown to have a role in thyroid, 
ovarian and renal cancer.  It is highly expressed in the kidney, so it is given the 
kidney cadherin (K-Cadherin).  
It was previously reported that GRS specifically binds to CDH6.  
Cleaving GRS different domains can give insight to where its active site is found.  
This could lead to a novel therapy for kidney cancer since there is no medication 
currently used directly to treat renal cancer.   
In this study, I found at active region of GRS and developed a peptide that 
binds to CDH6 inducing apoptosis.   By using modeling the binding sites were 
determined and validated by in-vitro screening.  Different lengths of peptide were 
tested in-vivo through different injection methods.  The xenograft mouse model 
having tumor suppressing effect toward CDH6-positive cell line only. By making a 








GRS derived fragment 4(F4) induces tumor regression by binding to CDH6 
To analyze which region of GRS has activity against tumor growth, four 
fragments of GRS were cut and cloned without interfering with the WHEP, 
catalytic and anti-codon binding domains of GRS(Fig. 1A-B). GRS fragments were 
purified and their binding to CDH6 was tested by pull-down assay.  Fragment 4 
(F4) was the only protein that showed CDH6 binding.(Fig. 1C). Four fragments 
were tested for anti-tumor effect on cell lines SN12C, MCF-7 and RAW264.7 cell 
lines.  The fragments had no cytotoxic effect on RAW264.7 or MCF-7 cells,  
CDH6 negative cell lines.  However, F4 did show cell killing effect toward SN12C, 
CDH6 positive cell line (Fig. 1D).. Based on this data the effect of F4 was further 
investigated 
 
N-terminal region of F4 is critical for anti-tumor activity 
 Due to seeing anti-cancer effect from F4, N-terminal region was truncated 
in order to reduce non-specific binding and conformation changes in F4. Because 
GRS N-terminal has beta sheet and inserted into the inner area of GRS, three 




length of N-terminal truncated form of F4s (for convenience, GRS-F4-N-terminal 
truncated formed was names GRS-F4-NT) were designed based on the structure, 
minimizing the conformation changes and retaining alpha and beta sheet in 
structure (Fig. 2A). The yield, anti-tumor activity of GRS, F4, GRS-F4-NT1, GRS-
F4-NT2, and GRS-F4-NT3 were measured to see which form of F4s is suitable to 
use to find CDH6 binding domain (Fig. 2B). When the N-terminal regions were 
truncated, the activity of F4 fragments decreased. Analysis of N-terminal truncated 
form of F4 on the anti-tumor activity gave a clue on the CDH6 binding site, which 
may locate from 526 residue to 558 residue. These results suggest that F4 is 
suitable for finding CDH6 binding domain.  
 
Structure-based docking model predicts the binding site of F4 and CDH6  
 F4 and CDH6 structure was used from Protein Data Bank (PDB) and the 
potential interaction domain of CDH6/F4 complex were predicted using the 
protein-protein docking software HADDOCK2.2. Based on the model run by the 
program, six residues were selected and point-mutated using opposite trend of 
amino acid (Fig. 3A). Residues containing arginine, the key of binding (a hotspot 
residue), was changed to alanine, which has negatively affected in binding. For 




interrupt the binding. Each mutant was purified and checked for the purity using 
Coomassie staining (Fig. 3B). CDH6 binding activity of F4 mutants were measured 
using ELISA having GRS used as control. Comparing to F4, F539E and E609A 
mutants had decreased in CDH6 binding activity and also showed decreased anti-
tumor activity (Fig. 3C-D).  
Confirming active site domain using stringent mutation. 
 The nearby residues were point-mutated into stringent mutant to increase 
the disruption in binding with CDH6 for determining the effect on binding and 
activity. In order to avoid structure conformational changes, stringent mutation was 
introduced in alpha helix structure and also outer part of F4. Tyrosine, 
phenylalanine and asparagine were mutated into glutamate or arginine for 
swapping the charges. Serine was also mutated into tryptophan to introduce bulky 
amino acid for disrupting the interface (Fig. 4A). Mutated F4 was purified before 
the experiment checking protein purity through Coomassie staining (Fig. 4B). 
Using ELISA having GRS as control, F535E showed dramatic decrease in binding 
and S568W and N570R also showed decrease in CDH6 binding activity (Fig. 4C). 
F535E residue showed no anti-tumor effects and S568W and N570R residues 
showed low cancer killing effect (Fig. 4D). Dramatic decrease in binding and anti-




area. These results suggest that F535 residue, along with S568 and N570 residues 
are involved in the CDH6 binding site.  
Double point mutation showing critical interaction between F4 and CDH6 
 F535, S568 and N570 residues were used for double point mutation. 
Structure model showed binding area could be divided into two areas 532 to 549 
and 568 to 597. To increase binding disruption, each area was double point 
mutated including F535, S568 and N570 residues (Fig. 5A). Double mutants and 
F4 were purified and purity of proteins was checked through coomassie staining 
(Fig. 5B). ELISA was used to check for CDH6 binding and double mutants having 
F535 (B-4 and B-5) showed dramatic decrease in binding and mutants with S568 
and N570 (A-1) also showed decreased in binding with CDH6 (Fig. 5C). Pull-
down assay was performed in order to confirm CDH6 binding. A-1, B-4 and B-5 
mutants showed same result with ELISA confirming that mutants associated with 
F535 and S548/N570 mutants showed dramatic decrease in binding when 
compared to F4 (Fig. 5D). A-1, B-4 and B-5 showed no anti-cancer effect showing 
that loss of binding with CDH6 could not induce anti-tumor effect (Fig. 5E). 





 A peptide was next designed to include all six residues identified from 
stringent mutation studies about the CDH6 binding domain. Peptide also has alpha-
helix on both ends to retain stability and conformation having two beta-sheets (Fig. 
6A). Peptide showed 80% of the CDH6 binding activity when compared to GRS 
(Fig. 6B). To see CDH6-dependent activity of peptide, CDH6 and pERK positive 
and negative cell lines were tested. Only CDH6 positive cell lines showed decrease 
in cell viability (Fig. 6C). CDH6 positive and negative renal cancer cell line was 
used to see peptide dose-dependent activity. Peptide showed activity toward CDH6 
expressing cell line, SN12C, in dose-dependent manner (Fig. 6D). To see if the 
peptide dephosphorylates ERK through CDH6 binding, CDH6 positive cell line, 
SN12C and negative cell line, RENCA, were used to check dephosphorylation of 
ERK (Fig. 6E-F). The melting temperature(Tm) was measured using thermal shift 
assay and peptide showed 53.44°C in melting temperature (Fig. 6G). Thus, it was 
found that GRS-derived peptide induces cancer cell death through 
dephosphorylation of ERK in CDH6 dependent manner.  
Peptide induces tumor regression in CDH6 positive cancer cell in vivo not in 
CDH6 negative cancer cell 
 To investigate the peptide effect toward CDH6-positive cell line in vivo, 




cells. CDH6-positive cell line, SN12C, and CDH6-negative cell line were injected 
into Balb/c nude mice, and tumors were grown until the average size reaches 
100mm3. On day 7 and day 9, PBS and 20 μg of GRS and peptide were directly 
delivered to the tumors for each group. Mice were harvested on day 17 and photo 
of mouse was taken along with mouse tumor weight. Compared to control, SN12C 
xenograft mouse model showed 75% decrease in tumor weight in GRS and peptide 
injected group, respectively (Fig. 7A-C). Mouse injected with GRS or peptide 
showed no changes in mouse weight change suggesting lack of toxicity (Fig. 7D). 
For RENCA xenograft mouse model, GRS and peptide had no effect toward tumor 
growth (Fig. 8A-C) and had no toxicity (Fig. 8D). 







Figure 1. GRS derived fragment 4(F4) induces tumor regression by binding to 
CDH6.  (A)Schematic representation for dividing full length GRS into four 
fragments sustaining WHEP, Catalytic, and Anti-codon Binding Domain.  (B) 
Each GRS fragment was presented with different color in GRS full-length structure 




CDH6 binding to fragments was tested using pull-down assay and western blotted. 
(D) Effect of GRS fragments on cell viability was tested using RAW264.7, MCF-7 





Figure 2. Analysis of F4 fragments to improve efficancy (A) Hydrophobicity 
model of F4 fragment (B) Point mutation based on delta G and binding was 
monitored at 0, 8, 15 days (C) Structure model of each N-terminal truncated of F4. 
Full length GRS, F4, F4-V1, F4-V2, and F4-V3 were designed and cell viability 
was tested to determine their efficacy. *Collaboration with Young Ho Jeon. 
 
Figure 3. Structure-based docking model predicts the binding site of F4 and 
CDH6 confirmed by in-vitro (A) Crystal structure for CDH6 and GRS F4 were 




body docking were found, followed by semi-flexible docking with different side-
chain rotamers. From 12 poses, Amber 14 was used to finalize docking model 
based on calculation of buried surface area that has short (10ns) molecular 
dynamics simulation. Based on docking model, predicted binding site were 
mutated for disrupt the binding interface. (B) Having GRS as positive control, F4 
and F4 mutants were coated with 2 μg/ml and CDH6 (2 μg/ml) binding was tested 
using ELISA. (C) CDH6 expressing cell line, H460, was treated with 100 nM of F4 
and F4 mutants for 24 h and the cell viability was measured by CCK8 assay. GRS 
100 nM was used as positive control to induce cell death.  (D) Peptide was coated 
with 2 μg/ml and checked CDH6 binding was tested using ELISA. GRS was used 
as a positive control. (E) CDH6 and pERK positive or negative cell lines were used 
to check cell viability using peptide 200 nM to see CDH6 dependency. 
Doxorubicin 100 nM was used as a positive control.  * Previously shown in Chanho 









Figure 4. Peptides were designed based on predicted active sites. (A) 70mer (B) 
25mer linear form without a linker. (C) 25 mer with added cysteine at the ends to 









Figure 5. Peptide induces tumor regression in CDH6 positive cancer cells only 
in vivo CDH6 positive cells, SN12C, were subcutaneously injected into the 
BALB/c nude mice and grown for 7 days until average tumor size reach 100 mm3. 
PBS, GRS (20 μg) and Peptide (20 μg) were intra-tumor injected (n=5, 
animal/group) day 7 and 9. Tumor volume was calculated as the longest diameter x 
the shortest diameter2 x 0.52. (A) Photographs of SN12C and RENCA xenograft 
tumors of PBS, GRS and peptide treated on day 7 and day 9 and monitored for 10 
days. Tumor weight and size were measured on the last day. (B, C) The mouse 




   
Figure 6. In-vitro experiments testing the activity and stability of designed 
peptides. (A)Peptide were treated H460 cells to monitor their effect on cell 
viability (B) ELISA plate was coated with peptides to analyze the binding effect to 




spectrometery was peformed to show the 2D structure of the peptides
 
Figure 7. GRS-derived small peptides induce tumor regression intra-tumor 
injection. CDH6 positive cells, SN12C, were subcutaneously injected into the 
BALB/c nude mice and grown for 5 days until average tumor size reach 100 mm3. 
PBS, GRS, 70mer, 25mer cyclic, 25mer linear and 8mer peptides (20 μg) were 
intra-tumor injected (n=5, animal/group) day 5 and 7. Tumor volume was 
calculated as the longest diameter x the shortest diameter2 x 0.52. (A, B) Tumor 




during tumor growth (D) Photographs of SN12C xenograft tumors of PBS, GRS 
and peptides. 
 
Figure 8. GRS-derived small peptides induces tumor regression intra-venous 
injection. CDH6 positive cells, SN12C, were subcutaneously injected into the 
BALB/c nude mice and grown for 5 days until average tumor size reach 100 mm3. 
PBS, GRS, 70mer, 25mer cyclic, 25mer linear and 8mer peptides (20 μg) were 
intra-tumor injected (n=5, animal/group) day 5 and 7. Tumor volume was 




weight and size were measured on the last day. (C) Mouse weight was monitored 






Figure 9. Labeled GRS-derived small peptides target tumor cells. GRS and 
GRS derived peptides were labeled with Alexa-fluor 590 were intravenously 
injected into balb/c nude mice. (A) Tumors were excised from mice and in vivo 
imaging system (IVIS) was used to monitor fluorescent activity. (B, C, D) The 


















Peptides are up-rising alternative targeting agents for human cancers (1). 
Peptide can resolve the problems that antibodies are facing, such as large size and 
nonspecific uptake by the reticuloendothelial system and liver (17). Antibodies are 
used for blocking the signal in cancer therapy, but peptides are used to activate 
signaling pathway through receptor binding. Development of peptides that activate 
the signal pathways by blocking tumor growth or inducing apoptosis can be a 
strategy used for cancer therapy (18). Peptide targeting cancer has been approved 
by Food and Drug administration (FDA) for past few years (2). Octreotide, a first 
approved peptide targeting somatostain receptor have been used for treating 
acromegaly and symptoms in cancer patient. Since then, more than 60 peptide 
drugs have been approved by FDA and more than 140 peptide drugs are in clinical 
trials (19). Therefore, targeting cancer using peptide can minimize side effects and 
can be beneficial for therapeutic drug development. 
GRS has been shown to have an anti-tumor effect through CDH6 binding 
by dephosphorylation of ERK. Therefore, finding CDH6 binding domain of GRS is 
important for development of peptide drug targeting CDH6/PP2A/ERK axis for 
cancer therapy (7). GRS binding receptor Cadherin-6, type II classical cadherin 




expresses higher level of CDH6 compare to normal (12, 20). Recently, antibody 
drug conjugate (ADC) targeting CDH6 for having high expression level in renal 
cancer are in clinical trial for targeting renal cancer drug (21). The drug 
development targeting renal cancer using CDH6 can be effective having high 
expression of CDH6 compare to normal. 
For therapeutic peptide development, anti-tumor or pro-tumor protein has 
been developed into peptide. Peptide derived from EGFR, P53, Bcl-2 and CXC 
chemokine is being developed into anti-tumor peptide for cancer treatment (22, 23). 
P53-derived peptide has been developed in order to induce necrosis of cancer cell 
developing mdm-2 binding site inducing mdm-2 and P53 competition and CKC 
chemokine derived peptide blocks basic components of angiogenesis (24, 25). 
Therefore, developing GRS binding domain into peptide for inducing cancer cell 
apoptosis through CDH6 binding. GRS-derived peptide that has anti-tumor activity 
for the development of renal cancer therapeutic drug. 
To determine CDH6 binding domain, GRS was divided into four 
fragments maintaining all existing domain and only fragment 4 (F4) showed CDH6 
binding and anti-tumor activities in vitro and in vivo. Due to F4 poor stability, N-
terminal of F4 inserted area of GRS and F4 fragment with different length of N-




terminal gets truncated, the activity of F4 decreased. These results gave an idea that 
the CDH6 binding domain may exist around N-terminal region of F4. To delineate 
the CDH6 binding domain, potential docking interface of CDH6/F4 complex were 
predicted using Haddock 2.2 (14). Predicted binding residues were mutated and 
F535, S568 and N570 residues showed loss of CDH6 binding and activity. For 
confirm binding domain, double point mutation was performed to increase 
disruption in CDH6 binding and F535 residue has been found to be critical for 
CDH6 binding.  
Based on the docking model prediction, peptide was developed having 
alpha helix segment on both ends and beta-strand-loop-beta strand to maintain 
stability and conformation (27, 28). Peptide showed CDH6 binding and CDH6 
dependent anti-tumor effects in dose dependent manner through dephosphorylation 
of ERK signal. Through mouse xenograft model, peptide showed tumor regression 
effect only toward CDH6 positive renal cancer cell. As a result, GRS-derived 
peptide showed binding toward CDH6 and anti-tumor effect toward renal cancer 
cell in vitro and in vivo. 
GRS-derived peptide has high possibility for renal cancer therapeutic drug 
development. Current cancer treatments are chemotherapy and/or radiation therapy, 




effectiveness of the cancer therapy (29, 30). Peptides have low toxicity and the 
ability to bind to different receptor for activating anti-tumor signaling are being 
magnified for the promising therapeutic drug (31). Renal cell cancer (RCC) is 
known for aggressive cancer that arises from the proximal renal tubular epithelium 
of the kidney and there are no specific RCC targeting drug (32). GRS-derived 
peptide can be used for the RCC specific targeting drug, having anti-tumor effect 
through binding to CDH6, which is highly expressed in renal cell cancer. Peptide 
can be used for the RCC therapeutic drug having CDH6 specificity and advantage 
of low toxicity of peptide.  In this study, full length GRS was developed into 8 and 
25 amino acids peptide sustaining anti-tumor effect by binding to CDH6 through 
dephosphorylation of ERK signaling. Also, it was shown the GRS peptide in vivo 
suppressed CDH6-positive tumor growth with low toxicity. This shows that GRS 
derived peptide is good drug candidate for cancers expressing CDH6.   
Peptides are up-rising alternative targeting agents for human cancers (1). 
Peptide can resolve the problems that antibodies are facing, such as large size and 
nonspecific uptake by the reticuloendothelial system and liver (17). Antibodies are 
used for blocking the signal in cancer therapy, but peptides are used to activate 
signaling pathway through receptor binding. Development of peptides that activate 




strategy used for cancer therapy (18). Peptide targeting cancer has been approved 
by Food and Drug administration (FDA) for past few years (2). Octreotide, a first 
approved peptide targeting somatostain receptor have been used for treating 
acromegaly and symptoms in cancer patient. Since then, more than 60 peptide 
drugs have been approved by FDA and more than 140 peptide drugs are in clinical 
trials (19). Therefore, targeting cancer using peptide can minimize side effects and 
can be beneficial for therapeutic drug development. 
GRS has been shown to have an anti-tumor effect through CDH6 binding 
by dephosphorylation of ERK. Therefore, finding CDH6 binding domain of GRS is 
important for development of peptide drug targeting CDH6/PP2A/ERK axis for 
cancer therapy (7). GRS binding receptor Cadherin-6, type II classical cadherin 
family, have been found preferentially expressed in kidney. Kidney cancer 
expresses higher level of CDH6 compare to normal (12, 20). Recently, antibody 
drug conjugate (ADC) targeting CDH6 for having high expression level in renal 
cancer are in clinical trial for targeting renal cancer drug (21). The drug 
development targeting renal cancer using CDH6 can be effective having high 
expression of CDH6 compare to normal. 
For therapeutic peptide development, anti-tumor or pro-tumor protein has 




chemokine is being developed into anti-tumor peptide for cancer treatment (22, 23). 
P53-derived peptide has been developed in order to induce necrosis of cancer cell 
developing mdm-2 binding site inducing mdm-2 and P53 competition and CKC 
chemokine derived peptide blocks basic components of angiogenesis (24, 25). 
Therefore, developing GRS binding domain into peptide for inducing cancer cell 
apoptosis through CDH6 binding. GRS-derived peptide that has anti-tumor activity 
for the development of renal cancer therapeutic drug. 
To determine CDH6 binding domain, GRS was divided into four 
fragments maintaining all existing domain and only fragment 4 (F4) showed CDH6 
binding and anti-tumor activities in vitro and in vivo. Due to F4 poor stability, N-
terminal of F4 inserted area of GRS and F4 fragment with different length of N-
terminal truncated forms were designed in order to increase stability (26). As N-
terminal gets truncated, the activity of F4 decreased. These results gave an idea that 
the CDH6 binding domain may exist around N-terminal region of F4. To delineate 
the CDH6 binding domain, potential docking interface of CDH6/F4 complex were 
predicted using Haddock 2.2 (14). Predicted binding residues were mutated and 
F535, S568 and N570 residues showed loss of CDH6 binding and activity. For 




disruption in CDH6 binding and F535 residue has been found to be critical for 
CDH6 binding.  
Based on the docking model prediction, peptide was developed having 
alpha helix segment on both ends and beta-strand-loop-beta strand to maintain 
stability and conformation (27, 28). Peptide showed CDH6 binding and CDH6 
dependent anti-tumor effects in dose dependent manner through dephosphorylation 
of ERK signal. Through mouse xenograft model, peptide showed tumor regression 
effect only toward CDH6 positive renal cancer cell. As a result, GRS-derived 
peptide showed binding toward CDH6 and anti-tumor effect toward renal cancer 
cell in vitro and in vivo. 
GRS-derived peptide has high possibility for renal cancer therapeutic drug 
development. Current cancer treatments are chemotherapy and/or radiation therapy, 
but the side effects caused by immune response or non-specific treatments limit the 
effectiveness of the cancer therapy (29, 30). Peptides have low toxicity and the 
ability to bind to different receptor for activating anti-tumor signaling are being 
magnified for the promising therapeutic drug (31). Renal cell cancer (RCC) is 
known for aggressive cancer that arises from the proximal renal tubular epithelium 
of the kidney and there are no specific RCC targeting drug (32). GRS-derived 




through binding to CDH6, which is highly expressed in renal cell cancer. Peptide 
can be used for the RCC therapeutic drug having CDH6 specificity and advantage 
of low toxicity of peptide.   
In this study, full length GRS was developed into 8 and 25 amino acids 
peptide sustaining anti-tumor effect by binding to CDH6 through 
dephosphorylation of ERK signaling. Also, it was shown the GRS peptide in vivo 
suppressed CDH6-positive tumor growth with low toxicity. This shows that GRS 
















MATERIALS AND METHODS 
Cell culture and materials 
H460, HCT116, and RENCA cells were grown in RPMI1640 medium and SN12C, 
MCF7 and HeLa cells were grown in DMEM. Cells were grown with 10% fetal 
bovine serum with 1% antibiotics at 37°C in a 5% CO2 incubator.  
Cell viability assay 
H460, HCT116, MCF7, HeLa, SN12C or RENCA cell line were seeded into 96 
well plate, 5000 cells/ml. Proteins were treated after 2 h with 100 μl serum free 
condition and incubated for 24 h. After 24 h, Cell Counting Kit-8 (CCK-8) assay 
(Dojindo Laboratories, Kumamoto, Japan) was performed. 10 μl of CCK8 solution 
was treated and after 1h O.D values was measured using microplate-reader 
(TECAN, Mannedorf, Swiss) at 450 nm. 
Mutagenesis 
Followed site-directed mutagenesis kit instructions (Agilent, Santa Clara, CA, 
USA). Primers were designed accordingly 37 mer with Tm greater than 78°C. For 
each mutant, 30 ng of F4 mutant DNA, 125 ng of primers, 2.25 mM of dNTP, 10x 
reaction buffer and 2.5 U/μl Pfu were mixed. Mixing and spinning down, PCR for 
95°C for 30 s, then 95°C for 30 s, 55°C for 1 min and 11 min 68°C for 18 cycles 
were performed. The reaction was then digested with 10U Dpn I for 37°C for 1 






F4 Protein purification (Batch) 
Transformation was performed into BL21 competent cell. After spreading into 
ampicillin plus agar plate, plate was incubated at 37°C overnight. Colony was 
picked into 3 ml of LB plus ampicillin and up-scaled into 1 L at 37°C. When O.D 
value reached 0.6, 1 mM of IPTG (Sigma, St. Louis, MO) was added and incubated 
overnight at 18°C. At 3500 rpm centrifugation for 30 min and pellet was collected 
using 7.8 pH buffer. 9 times of sonification were performed and centrifuged for 30 
min at 13000 rpm. Supernatant were collected and it was bound to 300 μl of 
glutathione agarose beads (Thermo, Waltham, MA) for 4 h or overnight.  The 
beads were washed 3 times with 8 ml of PBS and eluted with 500 μl of 40 mM pH 
8.0 L-Glutathione reduced (Sigma) for 2 to 4 hr.  The protein was dialyzed in PBS-
15% glycerol two times, 2 and 6 h or overnight respectively, and harvested.  The 
protein concentrations were measured using protein dye reagent (BioRad, Hercules, 
CA) at 595 nm spectrometer (Eppendorf, Hamburg, German) and purity was 
checked by Coomassi staining. 
CDH6 Protein purification (column) 
Pkk-CDH6-Fc vector (250 μg/100 ml) was transfected into HEK293F cells (2 x 106 
cells/ml) using Linear PEI (Polysciences, Warrington, PA). Cell was cultured at 
GIBCO FreestyleTM 293 (TECAN, Mannedorf, Swiss) media for 6 days in 8% CO2, 




for 15 min. Using bottle-top filter (Corning, Kennebunk, ME), supernatant was 
filter. Using CDH6 (100 ml) supernatant was bound to prewashed 250 μl Protein G 
agarose beads (Invitrogen, Carlsbad, CA) with 5 ml PBS for three times. The flow 
through was collected and reloaded to ensure proper binding of CDH6 to beads. 
The beads were then washed with 5 ml of PBS for a total of three washings.  CDH6 
was then eluted with 200 μl of 100 nM Glycine pH 2.5 (Affymetrix, Santa Clara, 
CA) into 20 μl 1M Tris pH 8.8 (Duchefa Biochemie, Haarlem, Netherlands) for 
neutralization and this step was repeated four times for a total of six elutions.  The 
protein concentrations were measured using protein dye reagent (BioRad, Hercules, 
CA) at 595 nm spectrometer (Eppendorf, Hamburg, German) and higher 
concentrations were pooled.  The protein was dialyzed in PBS-15% glycerol two 
times, 2 and 6 h or overnight respectively, and harvested.  
Haddock 2.2 docking program 
Crystal structures for CDH6 (pdb id: 3lnd, chain A) and GRS F4 (pdb id: 2pme, 
residues 256-674) were recovered from the protein data bank. Missing residues 
were modeled in to both structures using Modeler (15). Energy minimization was 
carried via the steepest descent and conjugate gradient methods using the Amber 
14 molecular modeling package (16). Potential CDH6/F4 complexes were 




Ambiguity Driven protein-protein DOCKing) (14). HADDOCK was used to 
generate 12 poses using rigid body docking, followed by semi-flexible docking 
with different side-chain rotamers. Each of the 12 poses was evaluated by visual 
inspection together with buried surface area calculations before and after a short 
(10 ns) MD simulation using Amber 14. The most stable and biologically realistic 
complex was thereby selected and used to predict interface mutations that may 
adversely affect binding. 
Pulldown assay 
Purified protein 4 μg and 30 μl of glutathione agarose beads (Thermo, Waltham, 
MA) were incubated for 2 h at 4°C. After three times of PBS washing, CDH6 2 μg 
was added and incubated for 4 h at 4°C. After the incubation samples were washed 
with PBS five times and boiled for 15 min. Sample was analyzed with 10% SDS-
PAGE and gel stained with Coomassie, followed by immunoblot analysis using 
anti-human antibody, 1:10000 (Thermo, Waltham, MA).  
Protein stability test  
Followed Proteostat Thermal shift stability assay kit instruction (Enzo Life Sience, 
Farmingdale, NY) 2 μg of protein was added with 2 μl of dye and 10x reaction 
buffer total volume of 20 μl. Each tube was mixed using pipet and transferred into 




temperature from 25 to 99°C with 0.3% degree difference in minutes. Experiment 
was performed using Thermal cycler diceTM Real Time system (Takara, Shiga, 
Japan) to find melting temperature for each protein and peptide. 
Xenograft Mice model 
Animal experiments were performed using the University Animal care and 
committee guidelines at Seoul Nation University. The tumorigenicity of HCT116, 
SN12C, and RENCA were tested using BALB/c nude female mice. 3 x 107 cells 
were injected to each mouse using a 20-gauge needle and allowed to grow up to 
100 mm3. Tumor growth was checked every 2 days, and when the tumor formation 
was observed using a caliper to measure tumor size. (Tumor volume was calculated 
as length x width2 x 0.52). When tumor size reached 100 mm2, proteins were 
injected in first day. Tumor weight and size were monitored every 2 days up to 12 
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Glycyl-tRNA Synthetase 펩타이드의 









우리는 대식세포에서 나온 GRS단백질이 종양형성에서 중요한 면역
감시기능에서 역할이 있다는 점을 보여주었다. GRS는 선천면역과 종양세포
사멸에 관여하는 것을 확인 하였다. 또한 GRS 유래 펩타이드를 통해 종양치
료에 쓰일수 있는 신약개발 후보군을 개발하였다. 
ARSs 단백질은 세포 내에서 tRNA에 상보적인 아미노산을 붙여주는 
역할을 하며 단백질 합성에 중요한 효소로 알려져 있다. 근래에 들어 ARSs 들




리고 세포사멸 등 여러 가지 기능을 하는 것으로 연구되고 있다. 이번 연구는 
GRS와 GRS유래 펩타이드가 종양형성에서 미치는 영향에 대해 집중하여 진
행을 하였다. 
첫 번째 파트에선, GRS가 스트레스 상황이 왔을 때 대식세포로부터 
분비되는 것을 확인 하였고 자가 분비 역할로써 CELSR2에 붙는 결과를 확인 
하였다. GRS가 CELSR2를 통하여 대식세포에 붙음으로써 MEK 신호전달 경
로를 활성화 시켰으며 관련된 사이토카인의 종류인 TNF-α, IL-6, 그리고 
CXCL10들이 증가함을 확인하였다. 결과적으로 대식세포는 M0에서 항암작
용을 나타내는 M1으로 바뀌었으며 그와 관련된 식 세포 활동을 확인하였다. 
종양이 개시되는 쥐 모델에서 GRS가 종양의 성장을 억제시켰으며 이 결과는 
GRS가 면역감시 역할에서 필요한 사이토카인으로써의 기능을 보여주었다. 
두번째 파트에선 GRS의 활성 도메인을 이용하여 펩타이드 약물을 개
발하였다. GRS는 알려져 있기로 CDH6를 발현하는 종양세포에 부착된 후 
ERK 신호전달 경로를 억제하여 세포사멸을 유도하는 것으로 연구되었다. 돌
연변이 생성작업을 통해 CDH6 에 결합하는 활성 도메인을 찾았으며 결과를 
토대로 합성 펩타이드를 in vitro와 in vivo에서 시험해 보았다. 펩타이드는 아




방법을 통해 확인하였다. 이 결과를 토대로 펩타이드가 종양치료의 약물후보
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